Yu-Wei Wang

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Acute Coronary Syndrome

Randomized Controlled Trial

Antiplatelet Therapy

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Yu-Wei Wang, Jie Xu, Likun Ma, Hao Hu, Hong-Wu Chen, Jing-Sheng Hua, Xiang-Yong Kong, Dan Li, Long-Wei Li, Jian-Yuan Pan, Jiawei Wu
Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study). BMJ open 14 (7) (2024)
Yu-Wei Wang, Jie Xu, Likun Ma, Hao Hu, Hong-Wu Chen, Jing-Sheng Hua, Xiang-Yong Kong, Dan Li, Long-Wei Li, Jian-Yuan Pan, Jiawei Wu
Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study). BMJ open 14 (7) (2024)
Yu-Wei Wang, Jie Xu, Likun Ma, Hao Hu, Hong-Wu Chen, Jing-Sheng Hua, Xiang-Yong Kong, Dan Li, Long-Wei Li, Jian-Yuan Pan, Jiawei Wu
Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study). BMJ open 14 (7) (2024)
Yu-Wei Wang, Jie Xu, Likun Ma, Hao Hu, Hong-Wu Chen, Jing-Sheng Hua, Xiang-Yong Kong, Dan Li, Long-Wei Li, Jian-Yuan Pan, Jiawei Wu
Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study). BMJ open 14 (7) (2024)